Screener
Acadia Pharmaceuticals
ACADAcadia Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative therapies for neurological and rare diseases.
Earnings
Next report
Nov 4, 2026 (in 2 months)Revenue estimate$332.3M
EPS estimate$0.21
Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Acadia Pharmaceuticals is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative therapies for neurological and rare diseases. The company focuses on addressing significant unmet medical needs through a portfolio of first-in-class treatments and a pipeline of late-stage clinical candidates.
Competitive position
Acadia holds a first-mover advantage in Parkinson’s disease psychosis and Rett syndrome with the only FDA-approved therapies for these specific indications.
GeographiesUnited States, Switzerland
Customer segmentsPatients, Healthcare Providers, Specialty Distributors
Business modelResearch and Development, Product Sales
SuppliersContract manufacturing organizations, Clinical research organizations, Scientific research institutions
CustomersSpecialty pharmacies, Wholesale distributors, Hospitals, Long-term care facilities
CountryUnited States of America
Listed2004
Employees610.0
CEOCatherine E. Owen Adams
SectorHealthcare
IndustryBiotechnology
Websiteacadia.com
FilingsSEC EDGAR
FAQ
- What is Acadia Pharmaceuticals's market cap?
- Acadia Pharmaceuticals (ACAD) has a market capitalization of $4.7B and trades on NASDAQ.
- What is Acadia Pharmaceuticals's revenue and profitability?
- Acadia Pharmaceuticals generated $1.1B in trailing twelve-month revenue with net income of $380.5M, representing a net margin of 33.4%. Gross margin stands at 91.1%, with free cash flow of $262.0M. The latest reported period is Q2 2026.
- Who are Acadia Pharmaceuticals's competitors?
- Acadia Pharmaceuticals's key competitors include Neurocrine Biosciences, Biogen, Zevra Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Where is Acadia Pharmaceuticals headquartered?
- Acadia Pharmaceuticals is headquartered in United States of America and employs approximately 610 people. It has been publicly traded since 2004.
